CombiGene is currently conducting two gene therapeutic development projects: one for treatment of epilepsy that cannot otherwise be treated with drugs and one for treatment of lipodystrophy, a rare condition characterized by an abnormal distribution of fatty tissue in the body.
CombiGene now has a well-established international network within both the pharmaceutical industry and academia. The ambition is to form strategic partnerships for continued development and commercialization of the two projects which CombiGene is currently pursuing and to identify potential new projects in areas in which it may be possible to apply gene therapy.
In order to prepare CG01 to meet the needs of a global submission the remaining preclinical program will be expanded and, in some parts, complemented with additional studies in collaboration with Spark
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714